3 Health Care Stocks Moving The Sector Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 86 points (-0.5%) at 16,084 as of Friday, April 11, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,014 issues advancing vs. 1,941 declining with 158 unchanged.

The Health Care sector currently sits down 0.7% versus the S&P 500, which is down 0.3%. Top gainers within the sector include Gilead ( GILD), up 4.5%, Merck ( MRK), up 0.8%, Biogen Idec ( BIIB), up 0.7%, Celgene Corporation ( CELG), up 0.7% and Amgen ( AMGN), up 0.6%. On the negative front, top decliners within the sector include Perrigo Company ( PRGO), down 1.8%, Shire ( SHPG), down 1.5%, Pfizer ( PFE), down 1.2%, Novartis ( NVS), down 1.0% and AstraZeneca ( AZN), down 0.9%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Allergan ( AGN) is one of the companies pushing the Health Care sector higher today. As of noon trading, Allergan is up $4.12 (3.5%) to $120.75 on heavy volume. Thus far, 2.4 million shares of Allergan exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $116.00-$121.96 after having opened the day at $116.47 as compared to the previous trading day's close of $116.63.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $36.2 billion and is part of the drugs industry. Shares are up 5.0% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Allergan a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Illumina ( ILMN) is up $4.51 (3.3%) to $140.25 on heavy volume. Thus far, 2.2 million shares of Illumina exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $129.11-$140.66 after having opened the day at $133.12 as compared to the previous trading day's close of $135.74.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $18.7 billion and is part of the drugs industry. Shares are up 22.7% year-to-date as of the close of trading on Thursday. Currently there are 7 analysts who rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Illumina Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Actavis ( ACT) is up $1.58 (0.8%) to $192.87 on average volume. Thus far, 1.8 million shares of Actavis exchanged hands as compared to its average daily volume of 2.8 million shares. The stock has ranged in price between $185.86-$194.93 after having opened the day at $187.73 as compared to the previous trading day's close of $191.29.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $35.2 billion and is part of the drugs industry. Shares are up 13.9% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts who rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. Get the full Actavis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Global Stocks Mixed, U.S. Futures Soften as Earnings, Oil, Rates Cloud Sentiment

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Deutsche Bank Plans 'Significant' Job Cuts as Q1 Profits Slump

Samsung Posts Record Q1 But Adds Cautious Voice To Smartphone Demand Forecasts

Samsung Posts Record Q1 But Adds Cautious Voice To Smartphone Demand Forecasts

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer